Immune Cell-Targeting Biologics for Alopecia Areata: A New Paradigm in Precision Medicine

The document reviews the potential of immune cell-targeting biologics as treatments for alopecia areata (AA), an autoimmune disorder causing hair loss. It evaluates several biologics, including rituximab, abatacept, alefacept, efalizumab, nivolumab, and aldesleukin. Rituximab and nivolumab showed complete hair regrowth in isolated cases, while abatacept reduced hair loss in some patients but was ineffective for extensive disease. Alefacept and efalizumab did not significantly outperform placebos in trials, though some individual cases showed regrowth. Aldesleukin did not show significant efficacy in trials, but a pilot study noted hair regrowth and improved quality of life. Overall, biologics targeting B and T cells showed moderate efficacy, indicating potential but highlighting the need for better-targeted therapies. Adverse events were mild across studies.